American Board of Internal Medicine (ABIM) Certification Practice Exam

What is the recommended follow-up interval for patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS)?

1. Monthly

2. Every 2-3 years

3. Every 6 months

4. Yearly

The correct answer is: Every 6 months

Monoclonal gammopathy of undetermined significance (MGUS) is a condition characterized by the presence of monoclonal proteins in the blood without associated symptoms or organ damage commonly seen in more severe plasma cell disorders. The recommended follow-up for patients with MGUS is typically every 6 to 12 months, with clinical practice often suggesting a 6-month interval for more vigilant monitoring, particularly during the early years following diagnosis. This follow-up schedule is crucial because while MGUS is generally asymptomatic and benign, there is still a risk of progression to more serious conditions such as multiple myeloma or other lymphoproliferative disorders. Regular monitoring allows for early detection should any changes or progression occur. The emphasis on a semi-annual follow-up reflects this cautious approach to managing individuals at risk, balancing the need for oversight without causing undue anxiety or disruption in a patient's life. Other follow-up intervals, such as yearly, may be deemed insufficient for catching early signs of progression, while more frequent intervals, such as monthly, may be unnecessarily burdensome for patients without providing substantial benefit. Thus, every 6 months aligns well with current clinical guidelines focusing on effective monitoring in MGUS patients.